Sequence:

References:

• Scott MG,Yan H,Hancock RE
  Infect Immun, 1999, 2005–2009
  
  
  Biological properties of structurally related alpha-helical cationic antimicrobial peptides
  
• Friedrich CL,Moyles D,Beveridge TJ,Hancock RE
  Antimicrob Agents Chemother, 2000, 2086–2092
  
  
  Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria
  
• Zhang L,Benz R,Hancock RE
  Biochemistry, 1999, 8102-8111
  
  
  Influence of proline residues on the antibacterial and synergistic activities of alpha-helical peptides.
  
• Rivas-Santiago B,Rivas Santiago CE,Castaneda-Delgado JE,León-Contreras JC,Hancock RE,Hernandez-Pando R
  Int J Antimicrob Agents, 2013, 143-148
  
  
  Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis.
  
• Hancock REW,Karunaratne N
  Patent US 6906035 B2, 2005,
  
  
  Antimicrobial Cationic Peptides
  
• Dean SN,Alvarez JAE,Zabetakis D,Walper SA,Malanoski AP
  bioRxiv, 2021,
  
  
  PepVAE3: variational autoencoder framework for antimicrobial peptide generation and activity prediction